Search
HMR4011
go.drugbank.com/drugs/DB06225ExperimentalHMR4011 (IPL 576,092) is a novel steroidal anti-inflammatory compound with a mechanism of action distinct from that of glucocorticoid.
Timbetasin
go.drugbank.com/drugs/DB19119InvestigationalTimbetasin is under investigation in clinical trial NCT05555589 (Assessment of the Safety and Efficacy of 0.1% RGN-259 Ophthalmic Solution for the Treatment of NK: SEER-2).
Synonyms: 3,11,25,31,38-pentakis(de-n6-acetyl)-1,22,30,33-tetrakis(de-o3-phosphono)thymosin .beta.4(human), Thymosin .beta.(4), 3,11,25,31,38-pentakis(de-n6-acetyl)-1,22,30,33-tetrakis(de-o3-phosphono)-MEM 1414
go.drugbank.com/drugs/DB05888ExperimentalMEM 1414 works by blocking phosphodiesterase, an enzyme that breaks down an important brain chemical, cyclic AMP. It appears to work in the area of the brain where new memories are formed.
Midostaurin
go.drugbank.com/drugs/DB06595ApprovedInvestigationalIt was approved on April 28, 2017 and has shown to increase the overall survival rate in patients with AML as an adjunct therapy along with chemotherapeutic agents.
Synonyms: 4'-N-benzoylstaurosporineFursultiamine
go.drugbank.com/drugs/DB08966ApprovedIt has also been suggested for several non-deficiency disorders but has not yet proven useful. Fursultiamine is a vitamin B1 derivative.
Plumbagin
go.drugbank.com/drugs/DB17048InvestigationalIt has been found that it inactivates the Akt/NF-kB, MMP-9 and VEGF pathways.[A253102]
Heptabarbital
go.drugbank.com/drugs/DB01354ExperimentalHeptabarbital is an intermediate or short term barbiturate used mainly for sedation and hypnosis.
Amediplase
go.drugbank.com/drugs/DB06679ExperimentalAmediplase is a recombinant chimeric plasminogen activator, consisting of the kringle 2 domain from the A-chain of tissue plasminogen activator (t-PA) and the carboxy terminal region of pro-urokinase.
Vanillyl butyl ether
go.drugbank.com/drugs/DB11299ApprovedIt is added to food products as a flavoring agent.
Rindopepimut
go.drugbank.com/drugs/DB05374InvestigationalRindopepimut (CDX-110) is an injectable peptide cancer vaccine which targets a mutant protein called EGFRvIII present in about 25% to 30% of glioblastoma cases. … The vaccine consists of the EGFRv3-specific peptide (a 13-amino acid mutant vIII epitope) conjugated to the non-specific immunomodulator keyhole limpet hemocyanin (KLH).